Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.
about
Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.Circulating microRNA profiles of Ebola virus infectionDeaths, late deaths, and role of infecting dose in Ebola virus disease in Sierra Leone: retrospective cohort studyProduction of individualized V gene databases reveals high levels of immunoglobulin genetic diversityAnti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona.The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus.An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions.Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants.Crimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological Infection.Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.Validation of the Filovirus Plaque Assay for Use in Preclinical StudiesEbola virus vaccines - reality or fiction?Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseasesEvaluation of Medical Countermeasures Against Ebolaviruses in Nonhuman Primate Models.Ebolavirus: An Overview of Molecular and Clinical Pathogenesis.Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease.Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates.Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.Vaccines against 'the other' Ebolavirus species.A Primate Model for Viral Hemorrhagic Fever.Humanized Mice--A Neoteric Animal Disease Model for Ebola Virus?From bench to almost bedside: the long road to a licensed Ebola virus vaccine.Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): Ebola virus diseaseAntiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing.Animal models for filovirus infections.Recently Identified Mutations in the Ebola Virus-Makona Genome Do Not Alter Pathogenicity in Animal Models.Animal Models of Ebolavirus Infection
P2860
Q28076034-92561F39-91A2-49F3-B183-3A9F5382DB37Q28392668-F04E39CF-F67C-4D8A-BCEA-86CBAAC8F887Q28394474-A24CB9B8-C9D6-467B-A1F7-A0B415BC6AC5Q28818629-53973022-1DF6-418E-BE9A-10F3458C381AQ30252022-8722820A-CDAB-41CD-A7F3-DF0DC1C29796Q33826350-0895D8EE-AFFB-4352-9AE8-ABACDC002550Q33919019-FD2E864F-4249-4475-8898-1BDE3DE0136BQ37118389-16CE0F2C-8812-4601-91C4-2AE3272F57A4Q37252982-0844E0AE-6072-48ED-929B-10A64314DCE4Q38603013-68DD46B8-6B05-42BA-8C7D-25ECC344E26BQ38686512-F32FC84B-C8DD-40E8-8511-FD57B0489685Q38711125-62ABF376-91CF-4C43-9E9E-00B93BEBDFF2Q38775636-143BADF4-505F-49D9-B315-7B370246706FQ38881265-25FB0BE9-82F4-4DFD-9F47-98B4FBFCAF5AQ39360987-E745B6B7-F3B2-4009-A449-955AAABF21D2Q40054394-11833697-DF8A-4A47-89BF-A80962C96AE2Q40054554-E0718514-ABBA-4570-9806-0E468C0E2DCAQ40061262-B2D630DB-81FC-461B-8FB5-43AC39F0D083Q40062330-E38D9635-B000-44A7-A02C-B988098E0185Q40091054-6B395D2A-4C94-4992-BA13-87494493B12AQ40093846-A1B6A8AF-62D2-4D57-8CB0-022AE457FC87Q40095257-96BCB3EF-170F-421D-A9B5-738981DB0E6EQ40112699-07A7FF77-036F-4E81-B210-5AB850E604B8Q41922365-CE9FE2AE-D1BB-43FD-9413-F6792A0A2117Q42560779-96D9033B-6E22-4B5B-8CD7-01E93F9FD331Q44106264-6CEE5769-803B-48F0-9780-EF445A93F604Q47159908-C5232EB4-2539-4099-866F-2A992D1672DFQ51782887-EC6B74D1-E3E7-492E-9F11-41837EAAC623Q52714949-D1AEC8F9-79CB-4AFF-80BB-A46F1F8F4DEEQ54108133-03C76D80-5DD2-49F3-A4F8-D70BB6FFB688Q54217122-EE21DFF2-77CA-4AA7-81A9-B5A90B2B21CBQ56541916-F8D005E6-07AA-41AB-9022-3CF2A64888C6
P2860
Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Considerations in the Use of N ...... s and Marburg Virus Infection.
@ast
Considerations in the Use of N ...... s and Marburg Virus Infection.
@en
type
label
Considerations in the Use of N ...... s and Marburg Virus Infection.
@ast
Considerations in the Use of N ...... s and Marburg Virus Infection.
@en
prefLabel
Considerations in the Use of N ...... s and Marburg Virus Infection.
@ast
Considerations in the Use of N ...... s and Marburg Virus Infection.
@en
P2860
P356
P1476
Considerations in the Use of N ...... s and Marburg Virus Infection.
@en
P2093
James E Strong
P2860
P356
10.1093/INFDIS/JIV284
P407
P478
212 Suppl 2
P577
2015-06-10T00:00:00Z